|
|
Allos Therapeutics (ALTH)
2 posts
• Page 1 of 1
Allos Therapeutics (ALTH)
by helios » Wed Mar 10, 2010 9:39 pm
Similarly, i'll pin up the notes later.
You do not have the required permissions to view the files attached to this post.
[Finance disclaimer: The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought regarding investing of any stocks/ funds and/or whatsoever. The author has no vested interest in the mentioned stock at the time of writing.
- helios
- Permanent Loafer
- Posts: 3608
- Joined: Wed May 07, 2008 8:30 am
Re: Allos Therapeutics (ALTH)
by helios » Thu Mar 11, 2010 9:46 pm
Folotyn (pralatrxate injection)
- a selective antifolate rationally designed for improved cancer cell update and retention
- the first and only FDA-approved therapy for relapsed or refractory peripheral T-cell lymphoma
- product is available since Oct 2009 with commercial launch in Jan 2010
Strategic life-cyle development plan intended to extend Folotyn's commercial opportunity and build additional value through potential expanded indications in U.S. and ex-U.S.
Exclusive worldwide rights for all indications
- composition of matter patent protection through 2017 in U.S. and E.U.
- potential 5-year extension under Hatch Wazman in U.S. and SPC in E.U.
- potential 6-months padiatric exclusivity extension
T-cell use patent through 2025 in U.S. and E.U.
Orphan drug designation in U.S. and E.U.
Oncology-focused biopharmaceutical company with experienced commercial and clinical management team
9/30/09 pro-forma cash of $177.1 M with no debts or warrants (includes net proceeds of $93 M from Oct 2009 financing)
- a selective antifolate rationally designed for improved cancer cell update and retention
- the first and only FDA-approved therapy for relapsed or refractory peripheral T-cell lymphoma
- product is available since Oct 2009 with commercial launch in Jan 2010
Strategic life-cyle development plan intended to extend Folotyn's commercial opportunity and build additional value through potential expanded indications in U.S. and ex-U.S.
Exclusive worldwide rights for all indications
- composition of matter patent protection through 2017 in U.S. and E.U.
- potential 5-year extension under Hatch Wazman in U.S. and SPC in E.U.
- potential 6-months padiatric exclusivity extension
T-cell use patent through 2025 in U.S. and E.U.
Orphan drug designation in U.S. and E.U.
Oncology-focused biopharmaceutical company with experienced commercial and clinical management team
9/30/09 pro-forma cash of $177.1 M with no debts or warrants (includes net proceeds of $93 M from Oct 2009 financing)
[Finance disclaimer: The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought regarding investing of any stocks/ funds and/or whatsoever. The author has no vested interest in the mentioned stock at the time of writing.
- helios
- Permanent Loafer
- Posts: 3608
- Joined: Wed May 07, 2008 8:30 am
2 posts
• Page 1 of 1
Who is online
Users browsing this forum: No registered users and 9 guests